Trial Profile
A retrospective study evaluating activity of Sunitinib in homogenous international cohort of metastatic chromophobe renal cell carcinoma patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Nov 2017
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 17 Nov 2017 New trial record